参考文献/References:
[1] Mills KT,Stefanescu A,He J. The global epidemiology of hypertension[J]. Nat Rev Nephrol,2020,16(4):223-237.
[2] 中国心血管健康与疾病报告编写组,胡盛寿. 中国心血管健康与疾病报告2022概要[J]. 中国循环杂志,2023,38(6):583-612.
[3] Yin R,Yin L,Li L,et al. Hypertension in China:burdens,guidelines and policy responses:a state-of-the-art review[J]. J Hum Hypertens,2022,36(2):126-134.
[4] Wang X,Zhang L,Li P,et al. Apelin/APJ system in inflammation[J]. Int Immunopharmacol,2022,109:108822.
[5] Chapman FA,Nyimanu D,Maguire JJ,et al. The therapeutic potential of apelin in kidney disease[J]. Nat Rev Nephrol,2021,17(12):840-853.
[6] Rossin D,Vanni R,Lo Iacono M,et al. APJ as promising therapeutic target of peptide analogues in myocardial infarction- and hypertension-induced heart failure[J]. Pharmaceutics,2023,15(5):1408.
[7] Xiong M,Chen H,Fan Y,et al. Tubular Elabela-APJ axis attenuates ischemia-reperfusion induced acute kidney injury and the following AKI-CKD transition by protecting renal microcirculation[J]. Theranostics,2023,13(10):3387-3401.
[8] Ma Z,Song JJ,Martin S,et al. The Elabela-APJ axis:a promising therapeutic target for heart failure[J]. Heart Fail Rev,2021,26(5):1249-1258.
[9] Li Y,Yang X,Ouyang S,et al. Declined circulating Elabela levels in patients with essential hypertension and its association with impaired vascular function:a preliminary study[J]. Clin Exp Hypertens,2020,42(3):239-243.
[10] Zhang Z,Tang J,Song J,et al. Elabela alleviates ferroptosis,myocardial remodeling,fibrosis and heart dysfunction in hypertensive mice by modulating the IL-6/STAT3/GPX4 signaling[J]. Free Radic Biol Med,2022,181:130-142.
[11] Chng SC,Ho L,Tian J,et al. ELABELA:a hormone essential for heart development signals via the apelin receptor[J]. Dev Cell,2013,27(6):672-680.
[12] Sharma M,Prabhavalkar KS,Bhatt LK. Elabela peptide:an emerging target in therapeutics[J]. Curr Drug Targets,2022,23(14):1304-1318.
[13] Xu C. The Elabela in hypertension,cardiovascular disease,renal disease,and preeclampsia:an update[J]. J Hypertens,2021,39(1):12-22.
[14] He L,Fu Y,Deng J,et al. Deficiency of FAM3D (family with sequence similarity 3 ,member D),a novel chemokine,attenuates neutrophil recruitment and ameliorates abdominal aortic aneurysm development[J]. Arterioscler Thromb Vasc Biol,2018,38(7):1616-1631.
[15] Dong QT,Ma DD,Gong Q,et al. FAM3 family genes are associated with prognostic value of human cancer:a pan-cancer analysis[J]. Sci Rep,2023,13(1):15144.
[16] Shen Y,Dong Z,Fan F,et al. Targeting cytokine-like protein FAM3D lowers blood pressure in hypertension[J]. Cell Rep Med,2023,4(6):101072.
[17] Yi X,Tran E,Odiba JO,et al. The formyl peptide receptors FPR1 and FPR2 as targets for inflammatory disorders:recent advances in the development of small-molecule agonists[J]. Eur J Med Chem,2024,265:115989.
[18] Kaur N,Gare SR,Shen J,et al. Multi-organ FGF21-FGFR1 signaling in metabolic health and disease[J]. Front Cardiovasc Med,2022,9:962561.
[19] Kaur N,Gare SR,Ruiz-Velasco A,et al. FGF21/FGFR1-β-KL cascade in cardiomyocytes modulates angiogenesis and inflammation under metabolic stress[J]. Heliyon,2023,9(4):e14952.
[20] Zhang Y,Liu D,Long XX,et al. The role of FGF21 in the pathogenesis of cardiovascular disease[J]. Chin Med J (Engl),2021,134(24):2931-2943.
[21] Gao Q,Xu L,Cai J. New drug targets for hypertension:a literature review[J]. Biochim Biophys Acta Mol Basis Dis,2021,1867(3):166037.
[22] Yang N,Zhang Y,Huang Y,et al. FGF21 at physiological concentrations regulates vascular endothelial cell function through multiple pathways[J]. Biochim Biophys Acta Mol Basis Dis,2022,1868(12):166558.
[23] Pan X,Shao Y,Wu F,et al. FGF21 prevents angiotensinⅡ-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1-7) axis in mice[J]. Cell Metab,2018,27(6):1323-1337.e5.
[24] Weng HC,Lu XY,Xu YP,et al. Fibroblast growth factor 21 attenuates salt-sensitive hypertension-induced nephropathy through anti-inflammation and anti-oxidation mechanism[J]. Mol Med,2021,27(1):147.
[25] Tan H,Yue T,Chen Z,et al. Targeting FGF21 in cardiovascular and metabolic diseases:from mechanism to medicine[J]. Int J Biol Sci,2023,19(1):66-88.
[26] Liccardo F,Luini A,Di Martino R. Endomembrane-based signaling by GPCRs and G-Proteins[J]. Cells,2022,11(3):528.
[27] Lino CA,Barreto-Chaves ML. Beta-arrestins in the context of cardiovascular diseases:Focusing on angiotensin Ⅱ type 1 receptor (AT1R)[J]. Cell Signal ,2022,92:110253.
[28] Lu S,He X,Yang Z,et al. Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design[J]. Nat Commun,2021,12(1):4721.
[29] Cao Y,van der Velden WJC,Namkung Y,et al. Unraveling allostery within the angiotensin Ⅱ type 1 receptor for Gαq and β-arrestin coupling[J]. Sci Signal,2023,16(797):eadf2173.
[30] Casadó-Anguera V,Casadó V. Unmasking allosteric-binding sites:novel targets for GPCR drug discovery[J]. Expert Opin Drug Discov,2022,17(8):897-923.
[31] Fu Y,Huang Y,Yang Z,et al. Cartilage oligomeric matrix protein is an endogenous β-arrestin-2-selective allosteric modulator of AT1 receptor counteracting vascular injury[J]. ?Cell Res,2021,31(7):773-790.
[32] Kashihara T,Kawagishi H,Nakada T,et al. β-arrestin-biased AT1 agonist TRV027 causes a neonatal-specific sustained positive inotropic effect without increasing heart rate[J]. JACC Basic Transl Sci,2020,5(11):1057-1069.
[33] Zhang X,Zhang S,Wang M,et al. Advances in the allostery of angiotensin Ⅱ type 1 receptor[J]. Cell Biosci,2023,13(1):110.
[34] Singh KD,Jara ZP,Harford T,et al. Novel allosteric ligands of the angiotensin receptor AT1R as autoantibody blockers[J]. Proc Natl Acad Sci U S A,2021,118(33):e2019126118.